Resmed Inc Stock Beta
| RME Stock | EUR 236.30 2.20 0.92% |
ResMed Inc fundamentals help investors to digest information that contributes to ResMed's financial success or failures. It also enables traders to predict the movement of ResMed Stock. The fundamental analysis module provides a way to measure ResMed's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ResMed stock.
ResMed |
ResMed Inc Company Beta Analysis
ResMed's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current ResMed Beta | 0.47 |
Most of ResMed's fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ResMed Inc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, ResMed Inc has a Beta of 0.4728. This is 45.02% lower than that of the Healthcare sector and 46.27% lower than that of the Medical Instruments & Supplies industry. The beta for all Germany stocks is notably lower than that of the firm.
ResMed Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ResMed's direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ResMed could also be used in its relative valuation, which is a method of valuing ResMed by comparing valuation metrics of similar companies.ResMed is currently under evaluation in beta category among its peers.
As returns on the market increase, ResMed's returns are expected to increase less than the market. However, during the bear market, the loss of holding ResMed is expected to be smaller as well.
ResMed Fundamentals
| Return On Equity | 0.24 | |||
| Return On Asset | 0.12 | |||
| Profit Margin | 0.22 % | |||
| Operating Margin | 0.28 % | |||
| Current Valuation | 31.17 B | |||
| Shares Outstanding | 146.91 M | |||
| Shares Owned By Insiders | 1.29 % | |||
| Shares Owned By Institutions | 66.53 % | |||
| Price To Earning | 41.49 X | |||
| Price To Book | 9.40 X | |||
| Price To Sales | 8.54 X | |||
| Revenue | 3.58 B | |||
| Gross Profit | 2.06 B | |||
| EBITDA | 1.19 B | |||
| Net Income | 779.44 M | |||
| Cash And Equivalents | 147.13 M | |||
| Cash Per Share | 1.03 X | |||
| Total Debt | 765.33 M | |||
| Debt To Equity | 61.30 % | |||
| Current Ratio | 2.06 X | |||
| Book Value Per Share | 25.45 X | |||
| Cash Flow From Operations | 351.15 M | |||
| Earnings Per Share | 5.17 X | |||
| Price To Earnings To Growth | 1.74 X | |||
| Target Price | 261.67 | |||
| Number Of Employees | 8.16 K | |||
| Beta | 0.47 | |||
| Market Capitalization | 29.28 B | |||
| Total Asset | 5.1 B | |||
| Z Score | 22.8 | |||
| Annual Yield | 0.01 % | |||
| Five Year Return | 1.34 % | |||
| Net Asset | 5.1 B | |||
| Last Dividend Paid | 1.72 |
About ResMed Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ResMed Inc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ResMed using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ResMed Inc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in ResMed Stock
When determining whether ResMed Inc is a strong investment it is important to analyze ResMed's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact ResMed's future performance. For an informed investment choice regarding ResMed Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ResMed Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.